Top Markets
#1 Merlin's Seal BTC Merlin's Seal BTC +42.87%
#2 Unipoly Unipoly +41.52%
#3 Useless Coin Useless Coin +30.00%
#4 0G 0G +29.98%
#5 SAFEcoin SAFEcoin +29.29%
#6 Zora Zora +22.15%
#7 Seeker Seeker +21.36%
#8 Dogs Dogs +21.33%
#9 Pons Pons +20.75%
#10 Fake World Assets Fake World Assets +17.63%
Coin of the day
Merlin's Seal BTC Merlin's Seal BTC
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Hansa Biopharma AB (publ) Hansa Biopharma AB (publ)

Hansa Biopharma AB (publ)

HNSA
Kedudukan dalam Saham #13534
Hansa Biopharma AB (publ) is a biopharmaceutical firm dedicated to developing... Hansa Biopharma AB (publ) is a biopharmaceutical firm dedicated to developing immunomodulatory therapies. Leveraging its unique enzyme technology platform, the company targets treatments that facilitate organ transplants and address rare autoimmune conditions driven by immunoglobulin G (IgG), alongside applications in gene therapy and cancer. Its primary drug candidate, Imlifidase, an enzyme therapy designed to cleave antibodies, is currently undergoing Phase 3 clinical trials for use in patients awaiting sensitized kidney transplants and those with anti-GBM antibody disease. Imlifidase is also in Phase 2 trials for treating antibody-mediated kidney transplant rejection and Guillain Barré syndrome. Further pipeline developments include NiceR (Novel immunoglobulin cleaving enzymes for Repeat dosing) for autoimmune diseases, transplantation, and oncology, as well as EnzE (Enzyme based antibody Enhancement) for cancer immunotherapy. Hansa Biopharma also has a preclinical research partnership with argenx BV, exploring the synergistic potential of their respective IgG-modulating technologies. Established in 2007, the company's headquarters are located in Lund, Sweden.
Harga Saham
$4.83
Modal Pasaran
$481.23M
Perubahan (1 hari)
-3.01%
Perubahan (1 tahun)
41.08%
Negara
SE
Perdagangan Hansa Biopharma AB (publ) (HNSA)

Kategori

Healthcare
Nisbah P/E bagi Hansa Biopharma AB (publ) (HNSA)
Nisbah P/E pada 2026 TTM: 0
Menurut laporan kewangan dan harga saham terkini Hansa Biopharma AB (publ), nisbah P/E semasa (TTM) ialah 0. Pada akhir 2026, syarikat mempunyai nisbah P/E sebanyak 0.
Sejarah nisbah P/E bagi Hansa Biopharma AB (publ) dari 2026 hingga 2026
Nisbah P/E pada akhir setiap tahun
Tahun Nisbah P/E Ubah
Tidak cukup data untuk tarikh yang disediakan.
Nisbah P/E untuk syarikat serupa atau pesaing
Syarikat Nisbah P/E Perbezaan Nisbah P/E Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Cara membaca nisbah P/E

Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.

Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.

Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.